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UV-spectroscopyAbstract The drug–protein interaction has been the subject of increasing interest over the decades.
In the present communication, the interaction of liver cystatin with anti-cancer (adriamycin) and
anti-hepatitis (adevoﬁr dipivoxil) drugs was studied by thiol-protease inhibitory assay, UV absorp-
tion, ﬂuorescence spectroscopy and circular dichroism (CD). A static type of quenching was
observed between the protein and the drug molecules. Binding constant (Ka) of adriamycin to liver
cystatin (LC) was found to be 1.08 · 106 M1. Moreover, binding site number was found to be 2.
Importantly, cystatin loses its activity in the presence of adriamycin. However, intrinsic ﬂuorescence
studies in the presence of adevoﬁr dipivoxil showed enhancement in the ﬂuorescence intensity sug-
gesting that binding of adevoﬁr to LC caused unfolding of the protein. The unfolding of the test
protein was also accompanied by signiﬁcant loss of inhibitory activity. CD spectroscopy result
showed, both adriamycin and adevoﬁr dipivoxil caused perturbation in the secondary structure
of liver cystatin. The possible implications of these results will help in combating drug induced
off target effects.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Drug–protein associations are vital, since most of the adminis-
tered drugs are reversibly bound to proteins. The bound drugs
are transported mainly as a complex with these proteins. The
binding factors are useful in studying the pharmacological
response and drugs dosage design (Borga and Borga, 1997).
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Figure 2 Chemical structure of adevoﬁr dipivoxil.
70 A. Shah et al.The present report summarizes the interaction of goat liver
cystatin (thiol-protease inhibitor) with an anti-sarcoma drug,
adriamycin and an anti-hepatitis drug, adevoﬁr dipivoxil. Adria-
mycin (doxorubicin hydrochloride) is an excellent anti-tumor
antibiotic and is very effective against a large number of human
malignancies. The anti-cancer activity of adriamycin is associ-
ated with the formation of intercalative complexes with DNA
(Bryn and Dolch, 1978).
Adevoﬁr dipivoxil is a diester prodrug of adevoﬁr. It is an
acyclic nucleotide analog having activity against human
hepatitis B virus (HBV). Moreover, it inhibits HBV-DNA
polymerase (reverse transcriptase) action via natural substrate
deoxyadenosine triphosphate binding and DNA chain termina-
tion. The chemical structure of adriamycin (doxorubicin hydro-
chloride) and adevoﬁr dipivoxil is shown in Figs. 1 and 2,
respectively.
Cystatins are the family of proteins that regulate and inhibit
the detrimental effect associated with cysteine proteases (Ekiel
et al., 1997). Cystatins could protect the cells from unnecessary
proteolysis which might lead to several pathological conditions
(Shah and Bano, 2009).
The goat liver cystatin used in the present study was puriﬁed
in our laboratory (Shah and Bano, 2011). Further, conforma-
tional changes in the puriﬁed thiol protease inhibitor after asso-
ciationwith anti-cancer and anti hepatitis drugs weremonitored
by UV–visible, ﬂuorescence and circular dichroism spectro-
scopic techniques. Moreover, the current paper also addresses
the kind of interaction involved in the binding of these drugs
with thiol protease inhibitor.
2. Materials and methods
2.1. Materials
Casein, papain, EDTA, acetone, sephacryl-S100HR, CBB
R-250 and cysteine were procured from Sigma Aldrich.
Adriamycin (doxorubicin hydrochloride) was purchased from
VHB Life Sciences Limited India. Adevoﬁr dipivoxil was pur-
chased from Sun Pharmaceutical Industries, India. All other
chemicals used were of analytical grade.O O
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Figure 1 Chemical structure of adriamycin (doxorubicin
hydrochloride).2.2. Methods
2.2.1. Protein estimation
The concentration of puriﬁed protein was quantitated by the
Lowry et al. (1951) method.
2.2.2. Preparation of drug solutions
As adriamycin (ADR) is sensitive to light and oxygen, a stock
solution of ADR within the therapeutic range in normal saline
was prepared just before use. 2 lM of goat LC was incubated
with varying concentrations of ADR in the range of 0.5–3 lM
for 30 min. Moreover, a stock solution of adevoﬁr dipivoxil in
0.05 M sodium phosphate buffer (pH 7.2) was prepared fresh
just before use. Goat liver cystatin at a concentration of
2 lM was incubated with varying concentrations of adevoﬁr
dipivoxil (0.1–1 lM) for 30 min.
2.2.3. Thiol protease inhibitory activity assay
Aliquots from the incubated samples were tested for their
thiol protease inhibition potential by the method of Kunitz
(1947).
2.2.4. UV–Visible spectroscopy
Absorption spectra of cystatin and cystatins incubated with
ADR and adevoﬁr dipivoxil were measured on a UV–visible
spectrophotometer at 220–400 nm wavelength range by the
use of 1 cm path length cell holder.
2.2.5. Fluorescence spectroscopy
The measurements of ﬂuorescence were recorded on a spectro-
ﬂuorometer (Shimadzu) at 25 C by the use of a quartz cell of
1 cm path length. The ﬂuorescence of cystatin bound drugs
was recorded at the wavelength range of 250–400 nm after
exciting the complex at 280 nm.
2.2.6. Circular dichroism measurement
Far-UV CD measurements were recorded by the use of a cir-
cular dichroismchiroptical spectrometer (Applied Photophys-
ics, Chira-scan-Plus, UK). Samples were maintained at 25 C
with the help of circulating water bath in a 1 mm quartz
cuvette. Spectra of LC in the absence and presence of various
concentrations of adriamycin and adevoﬁr dipivoxil were mea-
sured in the range 190–250 nm with a step size of 1.0 nm.
Figure 3 Fluorescence emission spectra of adriamycin–cystatin
complex in the presence of different concentrations of adriamycin
obtained in sodium phosphate buffer, pH, 7.5. Protein concen-
tration was 2 lM. Concentration of adriamycin was (from bottom
to top) 3 lM, 2 lM, 1 lM, 0.1 lM, respectively.
Figure 5 Determination of binding site by Stern–Volmer.
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3.1. Interaction of liver cystatin with adriamycin
Fluorescence measurements reveal information about the bind-
ing of small molecules with proteins, such as binding constant,
binding sites and binding mechanism. Binding of ADR with
goat liver cystatin caused quenching in the ﬂuorescence inten-
sity. The concentration increase of ADR resulted in the rise in
quenching of the cystatin-ADRcomplex. The ﬂuorescence emis-
sion spectra of the said complex in the presence of increasing
concentration of ADR have been illustrated in Fig. 3. The max-
imum quenching was observed at 3 lM adriamycin concentra-
tion. To determine the mechanism of binding between ADR
and goat liver cystatin the ﬂuorescence intensity data were ana-
lyzed by the Stern–Volmer equation (Shang et al., 2006).
The literature analysis illustrates two types of quenching
namely static and dynamic. Static quenching involves the for-
mation of a stable complex between the ﬂuor and quencher.Figure 4 Determination of types of quenching by Stern–Volmer
constant.On the other hand, in dynamic quenching the ligand hits with
excited ﬂuor, leading to loss of some energy.
The plot of F0/F vs [Q] exhibited a good linear relationship
indicating, the interaction was purely static in nature (Fig. 4).
The binding constant and the number of binding sites can
be determined by the equation given by Gao et al. (2004).
Log ðF0  FÞ=F½  ¼ Log Kþ n Log ½Q
where K and n are the binding constant and binding site
numbers, respectively. Binding constant was found to be
1.08 · 106M1 and the binding site number was found to be
2 as shown in Fig. 5.
3.2. UV–visible spectra of adriamycin cystatin complex
Absorption spectral measurements on liver cystatin in the pres-
ence of drugs provided information related to their interaction.
Difference spectra of drug protein complex were measured
against protein alone (Fig. 6). For the difference spectra
obtained at 0.1 lMADR, positive peaks at 260 nm might haveFigure 6 Light absorption spectra of adriamycin–cystatin com-
plex in the presence of different concentrations of adriamycin
obtained in sodium phosphate buffer, pH 7.5. Protein concentra-
tion was 1 lM. Adriamycin was tested in the concentration range
of (0.1–3 lM).
Table 1 Antiproteolytic activity of liver cystatin in the
presence of varying concentrations of adriamycin (ADR) after
incubation for 30 min.
Concentration
of ADR (lM)
% Remaining
inhibitory activity
% Loss of
inhibitory activity
0 100 0
0.1 80.2 ± 2.5 19
1 74 ± 1.4 26
2 58.2 ± 2.2 41.8
3 ND 100
The inhibitory activity of LC-I in the presence of ADR was assessed
by its ability to inhibit caseinolytic activity of papain as described
by Kunitz.
ND None detected.
*The inhibitory activity of the native liver cystatin (LC) was taken
as 100.
Concentration of LC was 1 lM. Figure 8 Light absorption spectra of adevoﬁr dipivoxil–cystatin
complex in the presence of different concentrations of adevoﬁr
dipivoxil obtained in sodium phosphate buffer, pH 7.5. Protein
concentration was 1 lM. Concentration of adevoﬁr dipivoxil was
(from bottom to top) 0.1 lM, 0.5 lM, 1 lM.
72 A. Shah et al.the contribution from phenylalanine. The negative peak at
210 nm observed for liver cystatin-ADR (LC-ADR) complexes
at 1, 2 and 3 lM ADR concentrations respectively may have
contributions from histidine residues (Donovan, 1969). The
intense negative peak at 260 nm for LC-ADR complexes is
indicative of involvement of phenylalanine and tyrosine in
complexation process. The broad shoulders at 290 nm are also
due to tryptophan and may contain contribution from phenyl-
alanine (Gao et al., 2004).
3.3. Inhibitory activity of adriamycin cystatin complex by papain
Changes in the inhibitory activity of LC after incubating for
30 min with increasing concentration of LC are shown in the
Table 1. The results show that liver cystatin lost complete
inhibitory activity at 3 lM concentration of adriamycin. ThisFigure 7 Fluorescence emission spectra of adevoﬁr dipivoxil–
cystatin complex in the presence of different concentrations of
adevoﬁr dipivoxil obtained in sodium phosphate buffer, pH 7.5.
Protein concentration was 1 lM. Concentration of adevoﬁr
dipivoxil was (from bottom to top) 0.1 lM, 0.5 lM, and 1 lM.suggests that increasing concentration of adriamycin resulted
in the functional inactivation of cystatin.
3.4. Fluorescence spectra of adevoﬁr dipivoxil cystatin complex
Binding of adevoﬁr dipivoxil with goat liver cystatin led to an
increase in the ﬂuorescence intensity of the goat liver cystatin
indicating that the binding caused unfolding of the protein as
shown inFig. 7.Maximumunfoldingwas observed at 1 lMcon-
centration of the drug. Increase in ﬂuorescence intensity was
also accompanied by a red shift of 5 nm which indicates pertur-
bation in the environment of aromatic residues and unfolding of
goat liver cystatin in the presence of adevoﬁr dipivoxil.
3.5. UV–visible absorption spectra of adevoﬁr dipivoxil cystatin
complex
UV–visible absorption difference spectra were computed at
varying drug concentrations from 0.1 lM to 1 lM. However,
profound changes were noted only for those obtained at
0.1 lM, 0.5 lM and 1 lM concentrations of drug. A sharp
negative peak noticeable at 210 nm in difference spectra
obtained at 0.1 lM adevoﬁr dipivoxil, suggests changes
around the histidine residues. A negative peak noticeable at
280 nm suggests changes around tyrosine residues (Donovan,
1969). Difference spectra of drug protein complex at 1 lM
drug concentration showed broad shoulder at 260 nm, indica-
tive of involvement of phenylalanine (Fig. 8).
3.6. Inhibitory activity of goat liver cystatin in the presence
adevoﬁr dipivoxil
Changes in the inhibitory activity of goat liver cystatin with
increasing concentration of adevoﬁr dipivoxil are shown in
Table 2. The results show that goat liver cystatin lost signiﬁ-
cant amount of inhibitory activity at 1 lM concentration of
adevoﬁr dipivoxil. Loss of inhibitory activity could be attrib-
uted to the modulation in the conformation of goat liver
cystatin.
Table 2 Effect of adevoﬁr dipivoxil on inhibitory activity of liver cystatin (LC) after incubation for 30 min.
Concentration of Adevoﬁr dipivoxil (lM) % Remaining inhibitory activity % Loss in Inhibitory activity of LC*
0 100 0
0.1 67 ± 1 33
0.5 42 ± 2 58
1 82 ± 1 18
The inhibitory activity of LC-I in the presence of ADP was assessed by its ability to inhibit caseinolytic activity of papain as described by
Kunitz.
Concentration of LC was 1 lM.
* The inhibitory activity of the native liver cystatin (LC) was taken as 100.
Figure 9 Circular dichroism spectra of liver cystatin in the absence and presence of various concentrations of adriamycin (a) and
adevoﬁr dipivoxil (b). The concentration of native liver cystatin was 0.2 mg/ml.
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measurement
Circular dichroism (CD) is a spectroscopic technique widely
used for the evaluation of the conformation and stability of
proteins in several environmental conditions and in the pres-
ence of various ligands. The obtained data showed negative
peak around 222 and 208 nm, indicating a-helical characteris-
tic of liver cystatin. However, after interaction with adriamycin
and adevoﬁr dipivoxil, ellipticity decreases with increasingconcentration of drugs (Fig. 9a and b). Secondary structural
change in the liver cystatin was found to be more pronounced
in the presence of anti-hepatitis drug (adevoﬁr dipivoxil)
compared with anti-cancer drug (adriamycin).
4. Conclusion
The conformational changes induced in goat liver cystatin
upon binding of adriamycin and adevoﬁr dipivoxil help in
addressing the kind of interactions involved in the binding.
74 A. Shah et al.Understanding the molecular basis of these interactions will
help in combating drug induced off target effects which in
the present case might be activation or dysregulation of
cysteine proteases.
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